Fiche publication
Date publication
septembre 2023
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BENSOUSSAN Danièle
,
Dr REPPEL Loïc
Tous les auteurs :
Fleta L, Gauthier M, Lider P, Campidelli A, Demoré B, Bensoussan D, Reppel L
Lien Pubmed
Résumé
Belonging to the family of advanced therapy medicinal products, CAR-T cells have changed the management of hematological malignancies. These treatments are known to involve many actors in a complex process. The quotation of hospital stays associated with this therapeutic strategy is also unusual since there is currently no specific quotation. From November 2021 to May 2022, a study was conducted at the Nancy University Hospital to evaluate the organizational impact of CAR-T cell therapy on hospital actors and the budgetary impact of stays in care centers. Through this study, we have shown significant and variable organizational impacts: from 3.12% of an additional full-time equivalent for an administrative manager to 41.5% for a clinical research associate. These times, when compared to the hourly rates of the actors, generated high costs: 6582.81 € per patient, i.e. 15.60% of the total cost of hospitalization. Taking into account the current refund of hospital stays and the costs calculated above, the balance of an average hospital stay is a deficit of 674.10 € [±10,224.79] with a median of 1334.97 €. This study highlighted the workload generated by the management of these new therapies, as well as the fragile balance of financing hospital stays. To date, it seems necessary and even essential to adapt the quotations of the acts dedicated to CAR-T cells activity and to provide adequate funding through an adapted pricing system.
Mots clés
Academic medical center, CAR-T cells, Centre hospitalier académique, Circuit hospitalier, Financial impacts, Hospital circuit, Impacts financiers, Impacts organisationnels, Organizational impacts
Référence
Bull Cancer. 2023 09 5;:
